Sign up Australia
Proactive Investors - Run By Investors For Investors

Botanix Pharmaceuticals concludes successful atopic dermatitis study

BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis.
a woman scratching her skin
Top line data indicates BTX 1204 was well-tolerated

Botanix Pharmaceuticals Ltd (ASX:BOT) has successfully completed a vehicle (placebo) controlled phase Ib study of BTX 1204 in patients with mild to moderate atopic dermatitis.

BTX 1204 is a novel topical formulation of synthetic cannabidiol that utilises Botanix’ proprietary drug delivery system Permetrex.

Twice as effective as the placebo

Top line data indicates BTX 1204 was well-tolerated as there were no significant adverse effects, or reports of skin irritation during the study.

Importantly, BTX 1204 was effective at reducing the key signs and symptoms of atopic dermatitis after only four weeks of treatment

After four weeks of treatment, 35% of patients receiving BTX 1204 achieved treatment success, compared to only 18% of patients who received the vehicle.

Potential new treatment option for atopic dermatitis

About 18 to 25 million people in the United States suffer from atopic dermatitis, including between 8% to 18% of infants and children.

Atopic dermatitis has been considerably under-diagnosed due to the lack of approved effective systemic agents, and limitations of current topical agents.

Botanix executive director Matt Callahan said: “BTX 1204’s efficacy profile is in line with existing topical products whose treatment success rates are typically between 25-35%.

This combined with the excellent safety profile demonstrated to date underlines the potential for BTX 1204 to be a very safe and exciting new treatment for the millions of patients who suffer from this disease.”

View full BOT profile View Profile

Botanix Pharmaceuticals Ltd Timeline

Related Articles

Zelda's Stewart Washer at Proactive's CEO Sessions
November 17 2017
Stewart Washer at Proactive's CEO Sessions this week.
Lung X-Ray
October 08 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
DNA sequence
July 12 2018
The cell therapy specialist also reported there had been industry interest around its main programmes

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use